Candriam S.C.A. Merus N.V. Transaction History

Candriam S.C.A.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$13.98 - $29.25 $685 - $1,433	-49 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$23.58 - $30.91 $1,155 - $1,514	49 New	49 $1,000
Q4 2021 Feb 10, 2022	SELL	$20.0 - $32.29 $940 - $1,517	-47 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$16.48 - $27.23 $49 - $81	3 Added 6.82%	47 $1,000
Q2 2021 Jul 20, 2021	BUY	$20.0 - $25.48 $880 - $1,121	44 New	44 $1,000

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $1.96B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.